ML-004
Autism Spectrum Disorder (ASD)
Phase 1Inferred Active
Key Facts
Indication
Autism Spectrum Disorder (ASD)
Phase
Phase 1
Status
Inferred Active
Company
About MapLight Therapeutics
MapLight Therapeutics is on a mission to redefine the standard of care for brain disorders by moving beyond broad neuromodulation to precise, circuit-specific therapeutics. The company has built a robust pipeline of six drug candidates, with its most advanced programs in Phase 2 trials for schizophrenia and Alzheimer's disease psychosis. Its strategy is anchored in a proprietary discovery platform co-founded by optogenetics pioneer Karl Deisseroth, which integrates cutting-edge technologies to translate deep neuroscience insights into targeted medicines for conditions like autism, Parkinson's, and schizophrenia.
View full company profileTherapeutic Areas
Other Autism Spectrum Disorder (ASD) Drugs
| Drug | Company | Phase |
|---|---|---|
| SCI-210 | SciSparc | Phase II |
| PAX-101 (IV Suramin) | PaxMedica | Phase 3 |
| eTNS Platform | NeuroSigma | Unknown |
| CM-AT | Curemark | Phase 3 |
| DT402 | Definium Therapeutics | Phase 2a |